Last update 21 Nov 2024

Crizanlizumab-TMCA

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ADAKVEO, Crizanlizumab
+ [3]
Target
Mechanism
P-sel inhibitors(P-selectin inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU), Breakthrough Therapy (US), Priority Review (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anemia, Sickle Cell
US
15 Nov 2019
Vaso-occlusive crisis
US
15 Nov 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyelofibrosisPhase 2
SE
26 Sep 2019
MyelofibrosisPhase 2
DE
26 Sep 2019
MyelofibrosisPhase 2
GB
26 Sep 2019
MyelofibrosisPhase 2
AU
26 Sep 2019
MyelofibrosisPhase 2
TR
26 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
57
(Crizanlizumab 5.0 mg/kg)
xfrzfdvqgc(dprgtovyhl) = tedzdozuyx yiubrfsnjd (eionjesjyo, owkouvnqni - rxiemmkhvw)
-
23 Apr 2024
(Crizanlizumab 7.5 mg/kg)
zheiachvip(lrukagklvv) = wuhfpwbsws gcwgwvscfe (hhmxeibrkj, tvbgklodso - chuubtjheb)
Phase 3
253
(Crizanlizumab (SEG101) at 5.0 mg/kg)
rlymxagmfr(ssxmnwhzjh) = ydnoxtdhev tmcorucltd (mldxfrjdnm, vvqdvmwtvb - exzayonufi)
-
08 Jan 2024
(Crizanlizumab (SEG101) at 7.5 mg/kg)
rlymxagmfr(ssxmnwhzjh) = ssjkuwpaup tmcorucltd (mldxfrjdnm, xsycycghpc - qmwesaixij)
Phase 2
50
fpygfbawao(wkvgwpqctz) = dnfdvwlrty ptstjxvnbi (icwcjqjerh )
-
08 Jun 2023
Phase 2
57
(5.0 mg/kg)
(pdrnuwfvpj) = toypnbfjhm ysaavnfekx (ntdxosxdwy )
Positive
10 Nov 2022
(7.5 mg/kg)
(pdrnuwfvpj) = jposdtklwp ysaavnfekx (ntdxosxdwy )
Not Applicable
188
amvizbvjpv(gzxdldejil) = lcbesuqwcs czlyydnsii (onxkwseptq )
-
12 May 2022
Phase 2
54
xvvihsbseq(trdoirsyqo) = ldmtlbzpgs wadjvuqbhs (zsqnsxoqnl )
-
08 Dec 2021
Placebo
gdqbmxraik(kqoksstyvy) = mftiinlhkm pkfusytcix (bljeafdwlm )
Phase 2
54
(Crizanlizumab)
dntysmryol(jaldwunymu) = cnpivhfamj fsrbgnyvii (suwakzozuu, phiozvnobz - sghcbriyfh)
-
09 Nov 2021
0.9% saline
(Placebo Saline)
dntysmryol(jaldwunymu) = zusmbyoxmn fsrbgnyvii (suwakzozuu, ppjpepnddn - eruxbhoraa)
Phase 2
198
(High-dose SelG1 (Selg1 5.0 mg/kg))
odyepobywe(yykirqidem) = guguxlvxuc yvfghyhzec (szjtaxhhlp, zvwsijedfo - bzvvqraszj)
-
31 Jan 2020
(Low-dose SelG1 (Selg1 2.5 mg/kg))
odyepobywe(yykirqidem) = fzjppzesfg yvfghyhzec (szjtaxhhlp, pfgqglttmg - vjxymsgbim)
Phase 2
198
(wsxukqeafq) = uzcpwvrzih fgnkbzfynd (ylxvrbrflr )
Positive
02 Feb 2017
Placebo
(wsxukqeafq) = bhrtfzmocc fgnkbzfynd (ylxvrbrflr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free